Cotreatment of Cancer Cell Line and Normal Cells with Tamoxifen and Curcumin Encapsulated in Nanocarrierin order to Investigate Apoptotic Changes and Their Cytotoxic Effects

Tamoxifen is the usual endocrine (anti-estrogen) therapy for hormone receptor-positive breast cancer inpre-menopausal women.A low incidence of side effects has been reported with tamoxifen, resulting in the proposalto use the antiestrogen as a preventive agent for breast cancer. Three separate clinical trials are currently under way--in the United States, Italy, and the United Kingdom. Current concerns about tamoxifen are the development of ratliver tumors during long-term treatment and an increased incidence of endometrial carcinomas observed in patients.Another concern is the development of drug resistance to long-term tamoxifen therapy. There is increased interest inboth determining the mechanism of drug resistance and evaluating new antiestrogens that may be more beneficial asa preventive, as an adjuvant therapy, or for the treatment of advanced breast cancer.Also curcumin(is found in thelipophilic extract of the rhizomes of turmeric) induces apoptosis involving bax/bcl-2 in human breast cancer.However, clinical tests have shown the bioavailability of conventional oral curcumin is low. Therefore thedevelopment of an efficient drug delivery system for curcumin is of considerable interest. Indeed, recent studies havedemonstrated that a curcumin delivery system based on nanoscience and nanotechnology increases the therapeuticpotential of this compound. The purpose of this study was Investigation of co-treatment effects of tamoxifen andcurcumin loaded in polymeric nanocarrier and tamoxifen loaded in polymeric nanocarrier on breast cancer cell lineand normal cell.tamoxifen and curcumin was loaded into Diblock nanocarier, and experimental effects of them wasinvstigated on MCF7 cell line.

کلیدواژه ها:

tamoxifen ، curcumin ، nanocarrier